Wei Ying, Xiong Jian, Li Xiao, Ling Fayang, Zhao Yi, Sun Yuxin, Yao Jin, Hu Jinqun, Yang Liyuan, Liu Yu, Qi Wenchuan, Liang Fanrong
College of Acupuncture-Moxibustion and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Cardiovasc Ther. 2025 Feb 13;2025:7134878. doi: 10.1155/cdr/7134878. eCollection 2025.
This systematic review and meta-analysis of randomized controlled trials (RCTs) is aimed at assessing the clinical efficacy and safety of stellate ganglion block (SGB) for angina pectoris (AP). PubMed, Embase, Cochrane Library, Web of Science, Chinese National Knowledge Infrastructure, China Science and Technology Journal Database, and Wanfang databases were comprehensively searched for RCTs investigating SGB treatment for AP. The retrieval time was from the establishment date of each database to October 10, 2024. The Cochrane risk of bias assessment tool was used to determine the methodological quality. Review Manager 5.4 software was employed for data analysis, and GRADEpro GDT software was utilized to evaluate the quality of evidence. Ultimately, six RCTs were included, encompassing 373 patients with angina. The overall methodological quality of the included studies was moderate, with the evaluation of evidence quality showing 12 low-quality and five extremely low-quality studies. The meta-analysis results demonstrated that compared with the control group, the experimental group had lower frequency and duration of AP, visual analog scale score, heart rate, detection rate of S-T segment elevation ≥ 0.1 mV on electrocardiogram (ECG) after 24 h of treatment, detection rate of abnormal T waves on ECG after 24 h of treatment, and S-T segment displacement on ECG after treatment. Furthermore, the experimental group exhibited lower serum Cardiac Troponin I levels, a decreased incidence of acute myocardial infarction (AMI) and rehospitalization, and improved clinical efficacy. However, none of the included studies reported SGB-related adverse events. SGB is effective in alleviating myocardial injury and reducing the incidence of AMI and rehospitalization in patients with AP. Nevertheless, the limited number and relatively low quality of included studies emphasize the requirement for more high-quality research to verify these conclusions.
这项对随机对照试验（RCT）的系统评价和荟萃分析旨在评估星状神经节阻滞（SGB）治疗心绞痛（AP）的临床疗效和安全性。全面检索了PubMed、Embase、Cochrane图书馆、Web of Science、中国知网、中国科技期刊数据库和万方数据库，以查找研究SGB治疗AP的RCT。检索时间为各数据库建库至2024年10月10日。采用Cochrane偏倚风险评估工具确定方法学质量。使用Review Manager 5.4软件进行数据分析，并使用GRADEpro GDT软件评估证据质量。最终，纳入了6项RCT，涉及373例心绞痛患者。纳入研究的总体方法学质量中等，证据质量评估显示12项低质量研究和5项极低质量研究。荟萃分析结果表明，与对照组相比，试验组的AP发作频率和持续时间、视觉模拟量表评分、心率、治疗24小时后心电图（ECG）上S-T段抬高≥0.1 mV的检出率、治疗24小时后ECG上异常T波的检出率以及治疗后ECG上的S-T段移位均较低。此外，试验组的血清心肌肌钙蛋白I水平较低，急性心肌梗死（AMI）和再住院发生率降低，临床疗效改善。然而，纳入研究均未报告与SGB相关的不良事件。SGB可有效减轻AP患者的心肌损伤，降低AMI和再住院发生率。尽管如此，纳入研究数量有限且质量相对较低，强调需要更多高质量研究来验证这些结论。
